Rhelion Life Sciences Issues New Canadian Patent for Psilocybin Drug Candidate
News related to:Rhelion Life Sciences Corp · 2 min read
Rhelion Life Sciences Corp., an Ontario-based company advancing innovation and research within the legal psychedelic sector, has announced the issuance of a new Canadian patent to its wholly owned subsidiary, Filament Health Corp. PEX010 is produced using Filament's proprietary and patented extraction, purification, and stabilization methods. The drug candidate is available in a standardized dosing range of 1, 5, and 25 mg from a single drug candidate, with a 0.5 mg dose to follow. This ensures consistent composition across every dose, every study, and every research site, supporting and supplying more than 80 academic and philanthropic research studies worldwide.
The issuance of this new Canadian patent further solidifies Rhelion Life Sciences’ position as a leading supplier of pharmaceutical-grade natural psilocybin. PEX010 is being developed to support clinical research and compassionate access programs at leading institutions worldwide. The company’s commitment to advancing the natural psychedelic drug discovery and development sector is evident in its comprehensive patent estate and ongoing research efforts.
On April 30, 2026, Rhelion Life Sciences Corp. completed its previously announced acquisition of Filament Health Corp., including its lead drug candidate, PEX010, and its patent portfolio. The acquisition has expanded the company’s intellectual property estate, which now stands at 78 issued patents across 13 patent families. This robust patent portfolio spans issued patents in the United States, Canada, Australia, Israel, Mexico, and Europe, covering extraction, purification, stabilization, standardized compositions, and delivery.
The intellectual property estate behind PEX010 is extensive, with the company believing it to be the most extensive patent estate in natural psilocybin. The new Canadian patent adds to the existing portfolio, which now includes 78 issued patents across 13 patent families. This comprehensive patent estate is crucial for protecting how PEX010 is made, ensuring that the drug candidate remains a unique and innovative product in the market.
Rhelion Life Sciences Corp. is a science and research-led company dedicated to advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the company is developing naturally derived psilocybin drug candidates, including its patented PEX010. The company supports and supplies more than 80 academic and philanthropic research studies worldwide, underscoring its commitment to innovation and research.
The issuance of the new Canadian patent is a significant milestone for Rhelion Life Sciences Corp. and its subsidiary Filament Health Corp. It strengthens the company’s position in the legal psychedelic sector and provides additional protection for its proprietary methods and drug candidate. The company’s continued focus on expanding its clinical research footprint and ensuring the availability of standardized, naturally derived psilocybin is a testament to its dedication to advancing the field of psychedelic research and development.
In conclusion, the issuance of the new Canadian patent to PEX010 further enhances the intellectual property estate of Rhelion Life Sciences Corp. and its subsidiary Filament Health Corp. This development is a critical step in the company’s ongoing efforts to support and supply leading institutions worldwide with standardized, naturally derived psilocybin for research and compassionate access programs.